NCT02164006已完成1 期
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Brentuximab Vedotin in Combination With TGR-1202, a Novel PI3K Delta Inhibitor, in Patients With Hodgkins Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Maximum Tolerated Dose acceptable for participants
研究概览
简要总结
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with brentuximab vedotin in patients with hodgkin's lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of Hodgkin's Lymphoma
- •Relapsed or refractory after an autologous stem cell transplant (ASCT) or at least two prior multi-agent chemotherapy regimens in patients not candidates for ASCT
- •Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
排除标准
- •Any major surgery, chemotherapy or immunotherapy within the last 21 days
- •Known hepatitis B virus, hepatitis C virus or HIV infection
- •Autologous hematologic stem cell transplant within 3 months of study entry. Patients who had prior Allogeneic hematologic stem cell transplant are excluded
研究组 & 干预措施
TGR-1202 + brentuximab vedotin
Experimental
TGR-1202 oral daily dose in combination with a fixed IV infusion of brentuximab vedotin
干预措施: TGR-1202 + brentuximab vedotin (Drug)
结局指标
主要结局
Maximum Tolerated Dose acceptable for participants
时间窗: 21 days (1 cycle of therapy)
To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities
次要结局
- Overall Response Rate(Up to 1 year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT02100852TG Therapeutics, Inc.19
已完成
1 期
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCLChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMantle Cell LymphomaNCT02268851Dana-Farber Cancer Institute45
已完成
1 期
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid TumorsRectal CancerGastrointestinal Stromal Tumor (GIST)Colorectal CancerPancreatic CancerGastric CancerEsophageal CancerNCT02574663TG Therapeutics, Inc.66
已完成
1 期
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic MalignanciesNon-Hodgkin's LymphomaPeripheral T-Cell LymphomaHodgkin's LymphomaChronic Lymphocytic LeukemiaNCT01767766TG Therapeutics, Inc.90
已完成
2 期
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT02983617Gilead Sciences36